Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Clin Cancer Res. 2011 Sep 14;17(21):6742–6753. doi: 10.1158/1078-0432.CCR-11-1142

Figure 2.

Figure 2

PSK stimulates CD107a mobilization and enhances the lysis of K562 tumor cells. (A) Representative dot plots showing expression of CD107a in NK cells in control and PSK-treated PBMC. The PBMC was stimulated with PSK (100 μg/ml) or control PBS for 24 hr. Then the cells were mixed with target K562 cells at 2:1 ratio. Anti-CD107a was added to the culture and incubated for 6 hr. (B) Summary graph showing the percentage (mean±SD) of CD107a positive NK cells from 3 different donors and treated with or without PSK stimulation. *, p<0.05 using two-tailed Student t test. (C) The lysis of K562 target tumor cells by PSK-stimulated or unstimulated PBMC. Shown are the percentages of specific lysis (mean±SD in triplicate wells) at the indicated E:T ratios. PBMC were stimulated with PSK (or control PBS) for 48 hr before the initiation of cytolytic assay. Difference between PBS and PSK group at different E:T ratio were analyzed using 2 way ANOVA. Similar results were obtained from three independent experiments using PBMC from 3 different donors.